V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310007852 | 310005035 | 1.79 | 68.5 | Curative (C) | 2017-11-15 | 2017-11-16 | Dacarbazine | 2 | N | 310019802 | OXALIPLATIN + MDG |
| 310007853 | 310008192 | null | 65.9 | Curative (C) | 2018-01-27 | 2018-03-05 | TOPOTECAN | null | null | 310019802 | TOPOTECAN |
| 310007854 | 310005036 | 1.6 | 62.2 | Curative (C) | 2015-09-04 | 2015-09-29 | Pemetrexed | 2 | N | 310019814 | BENDAMUSTINE |
| 310007855 | 310009858 | 1.68 | 69.95 | Curative (C) | 2015-04-05 | 2015-04-05 | Bendamustine + prednisolone | 02 | null | 310019816 | FLUDARABINE + MELPHALAN |
| 310007856 | 310009858 | 1.64 | 61 | Palliative (P) | 2017-03-01 | 2017-03-04 | ICE (no GCSF) | 02 | N | 310019816 | GEMCITABINE + OXALIPLATIN |
| 310007857 | 310005037 | 1.68 | 57 | Curative (C) | 2015-12-07 | 2015-12-14 | POUT TRIAL | 2 | N | 310019824 | METHOTREXATE HIGH DOSE |
| 310007858 | 310005037 | null | 68.7 | Disease modification (D) | 2017-11-28 | 2017-12-08 | LANREOTIDE | null | Y | 310019824 | METHOTREXATE HIGH DOSE |
| 310007859 | 310005037 | 1.59 | 65.4 | Disease modification (D) | 2016-05-26 | 2016-09-20 | Trastuzumab 21 day maintenance | 02 | N | 310019824 | CYCLO + DOXORUBICIN + VINCRISTINE |
| 310007860 | 310005039 | 1.76 | 72.8 | Curative (C) | null | 2018-02-26 | IVADo | N | N | 310019827 | MELPHALAN |
| 310007861 | 310010767 | 1.72 | 82.25 | Palliative (P) | 2014-02-06 | 2014-03-03 | Abiraterone | null | null | 310019831 | CHOEP |
| 310007862 | 310005041 | null | 57.4 | Palliative (P) | 2014-08-08 | 2014-09-05 | ATG | N | N | 310019841 | GEMCITABINE + VINORELBINE |
| 310007863 | 310005042 | null | 49.2 | Adjuvant (A) | 2016-09-27 | 2016-11-01 | Bevacizumab + Oxaliplatin +MdG | N | N | 310019841 | CVP |
| 310007864 | 310005044 | 1.7 | 79.4 | Palliative (P) | 2015-07-13 | 2015-11-18 | MVAC | 2 | N | 310019846 | DABRAFENIB + TRAMETINIB |
| 310007865 | 310009861 | 1.66 | 88.8 | Curative (C) | 2013-09-15 | 2013-10-17 | EP | 2 | N | 310019847 | TEMOZOLOMIDE |
| 310007866 | 310005045 | 1.7 | 74.4 | Palliative (P) | 2016-12-24 | 2016-12-24 | CTD Attenuated (Thalidomide 50mg) | 2 | N | 310019851 | ECHELON-2 TRIAL |
| 310007867 | 310005047 | 1.75 | 57 | Curative (C) | 2013-11-06 | 2013-11-12 | EOX | N | N | 310019858 | TOPOTECAN |
| 310007868 | 310009862 | null | 67.9 | Curative (C) | 2018-05-04 | 2018-08-22 | CYCLO + ETOPOSIDE + NELARABINE | N | null | 310019863 | BEP |
| 310007869 | 310005050 | 1.76 | 92.8 | null | null | 2017-07-20 | RITUXIMAB + prednisolone + VINBLASTINE + prednisolone | 02 | N | 310019865 | DABRAFENIB + TRAMETINIB |
| 310007870 | 310008202 | 1.53 | 65.1 | Curative (C) | 2018-01-23 | 2018-01-30 | PMitCEBO | 2 | N | 310019865 | ALEMTUZUMAB |
| 310007871 | 310005052 | 1.5 | 74.7 | Palliative (P) | 2017-12-31 | 2018-01-04 | LANREOTIDE | N | N | 310019870 | METHOTREXATE |
| 310007872 | 310008203 | 1.69 | 72.5 | Not known (9) | 2013-10-29 | 2013-11-05 | Carboplatin + Docetaxel | 2 | N | 310019870 | CYCLOPHOSPHAMIDE + VINBLASTINE |
| 310007873 | 310008203 | 1.67 | 69.2 | Neo-adjuvant (N) | 2017-03-28 | 2017-03-29 | Capecitabine | 2 | null | 310019870 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 310007874 | 310008203 | 1.58 | 63.9 | null | 2014-02-14 | 2014-02-21 | LANREOTIDE | N | N | 310019870 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 310007875 | 310008203 | 1.5 | 66.2 | Adjuvant (A) | null | 2014-01-31 | Everolimus 10mg | Y | Y | 310019870 | TOPOTECAN |
| 310007876 | 310008203 | 1.67 | 54 | Curative (C) | 2015-10-16 | 2016-06-04 | LANREOTIDE | 02 | N | 310019870 | ECX |
| 310007877 | 310005055 | 1.73 | 43.6 | null | 2017-03-24 | 2017-04-06 | VISMODEGIB | 01 | N | 310019897 | ETOPOSIDE + GEMCITABINE |
| 310007878 | 310005055 | 1.57 | 127.9 | Curative (C) | 2017-06-03 | 2017-06-06 | CETUXIMAB + IRINOTECAN + MDG | 2 | N | 310019897 | ENZALUTAMIDE |
| 310007879 | 310005056 | 1.57 | null | Curative (C) | 2016-09-23 | 2016-10-26 | CTD Attenuated (Thalidomide 50mg) | Y | null | 310019900 | METHOTREXATE |
| 310007880 | 310005057 | 1.65 | 54.1 | null | 2016-11-23 | 2017-01-13 | ICON8 TRIAL | N | N | 310019900 | BCG |
| 310007881 | 310005061 | 1.61 | 76.4 | Neo-adjuvant (N) | 2018-11-01 | 2018-11-20 | Olaparib | 02 | N | 310019902 | METHOTREXATE |
| 310007882 | 310005061 | 1.66 | 62.7 | Disease modification (D) | 2017-01-01 | 2017-01-18 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | N | 310019902 | METHOTREXATE HIGH DOSE |
| 310007885 | 310005062 | 1.73 | 71.1 | Palliative (P) | 2016-11-18 | 2016-11-18 | THALIDOMIDE | N | N | 310019926 | CETUXIMAB |
| 310007886 | 310005063 | 1.77 | 115 | Curative (C) | 2013-11-20 | 2013-11-25 | NIVOLUMAB | 02 | N | 310019928 | MVAC |
| 310007887 | 310008208 | 1.48 | 65 | Disease modification (D) | null | 2015-06-20 | Cetuximab + Radiotherapy Load | N | N | 310019928 | ATG + BUSULFAN + FLUDARABINE + THIOTEPA |
| 310007888 | 310005064 | 1.78 | 92.2 | Curative (C) | 2018-07-28 | 2018-08-02 | Capecitabine + Oxaliplatin 21day | 02 | N | 310019932 | INTERFERON |
| 310007889 | 310005065 | 1.82 | 70.8 | null | 2018-02-06 | 2018-02-09 | Irinotecan + Modified De Gramont | N | N | 310019932 | IRINOTECAN + MDG |
| 310007890 | 310005065 | 1.78 | 46.8 | Neo-adjuvant (N) | 2014-08-31 | 2014-09-27 | DABRAFENIB + TRAMETINIB | 02 | N | 310019932 | RMS 2005 TRIAL |
| 310007891 | 310005066 | null | 53 | Curative (C) | 2018-06-03 | 2018-06-07 | Sunitinib | null | null | 310019942 | MITOTANE |
| 310007892 | 310005067 | 1.69 | 93.3 | Curative (C) | 2015-01-16 | 2015-01-20 | R IVAC | 2 | N | 310019947 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310007893 | 310009871 | null | 47.6 | Palliative (P) | 2014-02-27 | 2014-02-27 | Alemtuzumab | N | N | 310019954 | LENALIDOMIDE |
| 310007894 | 310005068 | 1.8 | 69.4 | Palliative (P) | null | 2014-02-03 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | null | 310019955 | IPILIMUMAB + NIVOLUMAB |
| 310007895 | 310009872 | 1.72 | 0 | Palliative (P) | 2016-02-29 | 2016-02-29 | Cisplatin + Etoposide (5 day) | N | N | 310019956 | OXALIPLATIN + MDG |
| 310007896 | 310011287 | 1.67 | 56.6 | Palliative (P) | 2016-05-16 | 2016-05-29 | ICON8 TRIAL | null | N | 310019959 | CARBO + FLUOROURACIL |
| 310007897 | 310005070 | null | 94.6 | Palliative (P) | 2016-08-22 | 2016-08-23 | Atezolizumab | 2 | N | 310019960 | PERTUZUMAB + TRASTUZUMAB |
| 310007898 | 310008213 | null | 66.6 | Palliative (P) | 2016-08-21 | 2016-08-28 | Cytarabine HD + Methotrexate HD | 02 | N | 310019962 | IVA |
| 310007899 | 310005072 | 1.69 | 50 | Palliative (P) | 2016-09-03 | 2016-09-21 | Methotrexate High Dose (3g/m2) | N | N | 310019963 | CAPECITABINE |
| 310007900 | 310005073 | null | 49.2 | Palliative (P) | 2014-01-07 | 2014-05-12 | Cyclophosphamide Fludarabine (Oral) | N | N | 310019969 | BENDAMUSTINE |
| 310007901 | 310005074 | 1.6 | 82 | Palliative (P) | 2017-04-28 | 2017-11-13 | Cisplatin + Etoposide po | 2 | N | 310019970 | OXALIPLATIN + MDG |
| 310007902 | 310005075 | 1.74 | null | Curative (C) | 2015-04-15 | 2015-09-21 | Capecitabine | N | N | 310019971 | DACARBAZINE |
| 310007903 | 310005075 | null | 132.4 | Neo-adjuvant (N) | 2016-08-21 | 2016-09-06 | ICE + GCSF | N | N | 310019971 | DHAP |